Technical Approval Sample Clauses

Technical Approval. 8.1 Subject to his satisfaction the Director will grant Technical Approval for all the Engineering Drawings and any associated reports and / or specifications 8.2 ANY works carried out prior to the granting of Technical Approval of the Engineering Drawings and any associated reports and specifications will be carried out at the Owner and Developer’s risk
Sample 1Sample 2
AutoNDA by SimpleDocs
Technical Approval. Technical approval will not be granted until the various consultations, i.e., street lighting, drainage and highway landscaping have been agreed. At this stage, the bond will be calculated at 110% of the total cost of works plus commuted sums, using WCC rates. The inspection fees will be calculated as follows: • 8.5% of the bond (excluding commuted sums) should the developer agree to not commence Section 38 works until technical approval has been granted. • +1% over and above the 8.5% every calendar month, that the developer wilfully constructs Section 38 works without the benefit of technical approval. It is possible that a Section 38 inspector may be released to site prior to technical approval being granted, but the following conditions must be met: • The long sections are required to be approved. • The construction details are required to be approved. • CBR’s and PI testing are to have been carried out, and the design CBR and construction depths agreed with the Engineer. (N.B. If PI testing has not been carried out then a capping layer of 600mm will be assumed). • The 8.5% fees will have been paid (with the balance to be paid on signing of the agreement). Provisional commuted sums will be calculated using the method below, with the final balance to be paid prior to adoption.
Sample 1Sample 2
Technical Approval. 2.1. Domains of use accepted in construction 2.2. Appreciations on product 2.2.1. The ability to exploit in construction Composite manhole covers and gully gratings, Mechanical resistance and stability Fire safety Hygiene, health and environment Safety and accessibility in exploitation Energy saving and thermal insulation Noise protection Sustainable use of natural resources
Sample 1

Related to Technical Approval

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Contractor Licensing, etc. Notwithstanding Section 14.c, District may terminate this Contract immediately by written notice to Contractor upon denial, suspension, revocation, or non-renewal of any license, permit, or certificate that Contractor must hold to provide services under this Contract.

  • Final Approval Hearing “Final Approval Hearing” shall mean the hearing at which the Court will consider and finally decide whether to enter the Final Judgment.

  • Regulatory Approvals Each party shall use all reasonable efforts to file, as promptly as practicable after the date of this Agreement, all notices, reports and other documents required to be filed by such party with any Governmental Body with respect to the Merger and the other transactions contemplated by this Agreement, and to submit promptly any additional information requested by any such Governmental Body. Without limiting the generality of the foregoing, the Company and Parent shall, promptly after the date of this Agreement, prepare and file the notifications required under the HSR Act in connection with the Merger. The Company and Parent shall respond as promptly as practicable to (i) any inquiries or requests received from the Federal Trade Commission or the Department of Justice for additional information or documentation and (ii) any inquiries or requests received from any state attorney general or other Governmental Body in connection with antitrust or related matters. Each of the Company and Parent shall (1) give the other party prompt notice of the commencement of any Legal Proceeding by or before any Governmental Body with respect to the Merger or any of the other transactions contemplated by this Agreement, (2) keep the other party informed as to the status of any such Legal Proceeding, and (3) promptly inform the other party of any communication to or from the Federal Trade Commission, the Department of Justice or any other Governmental Body regarding the Merger. The Company and Parent will consult and cooperate with one another, and will consider in good faith the views of one another, in connection with any analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal made or submitted in connection with any Legal Proceeding under or relating to the HSR Act or any other federal or state antitrust or fair trade law. In addition, except as may be prohibited by any Governmental Body or by any Legal Requirement, in connection with any Legal Proceeding under or relating to the HSR Act or any other federal or state antitrust or fair trade law or any other similar Legal Proceeding, each of the Company and Parent will permit authorized Representatives of the other party to be present at each meeting or conference relating to any such Legal Proceeding and to have access to and be consulted in connection with any document, opinion or proposal made or submitted to any Governmental Body in connection with any such Legal Proceeding.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!